Sean M. Healey & AMG Center for ALS

Overview

The Healey & AMG Center for ALS leads one of the world’s most active and comprehensive ALS research programs, with hundreds of research studies underway at any given time. Under the leadership of Merit Cudkowicz, MD, MSc, and guided by a Science Advisory Council (SAC) of international experts, the Center is tireless in its pursuit of a cure.

Since 1993—when a research team at Massachusetts General Hospital identified the first ALS‑associated gene—the Center has remained at the forefront of ALS discovery. Its teams continue to advance new treatments, develop better biomarkers, and improve clinical trial designs to move promising therapies forward faster.

The Healey & AMG Center specializes in translating scientific discoveries into real clinical progress. Research efforts span cell and gene therapies, targeted antibodies, machine learning, and small‑molecule therapeutics — all aimed at slowing or stopping the drivers of ALS. Because ALS affects each person differently, The Center uses precision‑medicine approaches to match therapies to an individual’s unique biology.

What makes the Healey & AMG Center unique is its fully integrated model that brings together scientists, clinicians, engineers, and people living with ALS to accelerate breakthroughs from the laboratory to clinical trials. The Center also invests deeply in the next generation of ALS leaders through global fellowships, innovation prizes, and training programs.

The mission of the Healey & AMG Center is bold and simple: to speed the development of treatments that slow, halt, repair, and ultimately prevent ALS.